

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

33  
33  
66

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 November 2001 (29.11.2001)

PCT

(10) International Publication Number  
**WO 01/89589 A1**

(51) International Patent Classification<sup>7</sup>: **A61L 9/04**,  
A61K 31/135, 31/13

[US/US]; University of California, Irvine, 360 Med Surge  
II, Irvine, CA 92697-4625 (US).

(21) International Application Number: PCT/US01/16880

(74) Agent: **EINHORN, Gregory, P.**; Fish & Richardson P.C.,  
Suite 500, 4350 La Jolla Village Drive, San Diego, CA  
92122-1243 (US).

(22) International Filing Date: 23 May 2001 (23.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/206,591 23 May 2000 (23.05.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:

US 60/206,591 (CON)  
Filed on 23 May 2000 (23.05.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **THE  
REGENTS OF THE UNIVERSITY OF CALIFORNIA**  
[US/US]; Office of the President, 1111 Franklin Street,  
12th Floor, Oakland, CA 94607-5200 (US).

Published:

— with international search report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **PIOMELLI, Daniele**

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: A NOVEL TREATMENT FOR COUGH

(57) Abstract: The invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough. Locally acting cannabinoid agents can be administered to the airways of a subject to ameliorate cough, without causing the psychoactive effects characteristic of systemically administered cannabinoids. In addition, locally or systemically administered cannabinoid inactivation inhibitors can also be used to ameliorate cough. The present invention also defines conditions under which cannabinoid agents can be administered to produce anti-tussive effects devoid of bronchial constriction.

WO 01/89589 A1

# **A NOVEL TREATMENT FOR COUGH**

## **RELATED APPLICATIONS**

This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S.  
5 Provisional Application 60/206,591, filed May 23, 2000. The aforementioned  
application is explicitly incorporated herein by reference in its entirety and for all  
purposes.

## **STATEMENT AS TO FEDERALLY SPONSORED RESEARCH**

This invention was made with Government support under a grant from the  
10 National Institutes of Health. The Government may have certain rights in this  
invention.

## **TECHNICAL FIELD**

This invention relates to pharmaceutical compositions for preventing the  
initiation of cough and methods for using the compositions for the treatment of cough.  
15 More particularly, the invention relates to the local administration of a therapeutically  
effective amount of a pharmaceutical composition comprising at least one direct or  
indirect cannabinoid receptor agonist to produce an anti-tussive effect without  
significant delivery of the agonist(s) to the systemic circulation.

## BACKGROUND

Administration of the main active constituent of the cannabis plant,  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC), produces in animals and humans alleviation of cough and bronchospasm, which suggest a possible application of cannabis-like (cannabinoid) compounds for the treatment of cough. The potential therapeutic value of this observation is hindered, however, by two factors. First, the systemic administration of cannabinoid compounds produces significant psychoactive effects (for example, memory impairment, dysphoria, alteration in the perception of time, and habit formation). Second, some asthmatic patients who receive  $\Delta^9$ -THC respond to this compound with a paradoxical bronchial constriction. Therefore, there exists a need for compounds, or pharmaceutical preparations thereof, which can prevent or alleviate cough in animals and humans without producing significant psychoactive effects.

## SUMMARY OF THE INVENTION

In one general aspect, the present invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough. Further, the invention teaches that local administration of locally acting cannabinoid agents in the airways reduce cough, without causing the psychoactive effects characteristic of systemically administered cannabinoids. Even further, the present invention defines conditions under which cannabinoid agents can be administered to produce anti-tussive effects devoid of bronchial constriction. Specifically, the invention demonstrates that cannabinoid compounds produce

bronchial constriction when the intrinsic constricting tone of the vagus nerve is reduced or eliminated.

In another aspect, the present invention also teaches the local or systemic use of cannabinoid inactivation inhibitors, alone or in conjunction with a cannabinoid  
5 receptor agonist, to ameliorate cough.


The pharmaceutical compositions and methods of the present invention are characterized by their ability to inhibit cough initiation and/or signaling from the upper airways to the central nervous system. Specifically, the present invention results in the peripheral inhibition of cough signaling. Without being bound by any  
10 theory, it is believed that the pharmaceutical compositions of the present invention short-circuit the intracellular signaling cascade initiating cough by activating CB1 cannabinoid receptors found in the upper airways of mammals. The present invention regulates cough signaling at the periphery by the activation of local CB1 cannabinoid receptors where it is believed that endogenous cannabinoids participate in filtering  
15 emerging cough signals within the upper airways. The present invention unexpectedly achieves the above superior desired anti-tussive effects without the dysphoric side effects and habit-forming properties characteristic of centrally acting cannabimimetic or opiate drugs.

The invention provides a method for ameliorating or preventing cough in a  
20 subject, wherein the method comprises administration to the subject of a cannabinoid receptor agonist having anti-tussive properties without any significant psychoactive effects. The subject may be animal or human. As an example, one method of treating cough in a mammal may comprise topically administering into the upper airways (for

example, by aerosol) an effective amount of at least one locally acting cannabinoid receptor agonist in a pharmaceutically acceptable excipient for topical administration.

In the methods of the invention, a cannabinoid receptor agonist, or a pharmaceutical composition thereof, in accordance to the present invention can

5 include cannabinoid receptor agonists having the general formula I:



wherein X is N-R1 or O;

R is a saturated or unsaturated, chiral or achiral, cyclic or acyclic, substituted  
10 or unsubstituted hydrocarbyl group with 11 to 29 carbon atoms, optionally incorporating up to 6 oxygen or sulfur atoms;


R1, R3 and R4 are selected independently from hydrogen, alkyl (C1-4), alkenyl (C2-4), alkynyl (C2-4), cycloalkyl (C3-6), or hydroxyalkyl group with from 2 to 4 carbon atoms;

15 R2 is OH or O-CO-alkyl, where the alkyl group has from 1 to 4 carbon atoms;  
and

n is selected from 2 to 4.

When R<sub>2</sub> is OH and X is N-H, they may be combined through the carbonyl group to form a heterocyclic ring structure, *e.g.* an oxazolidinone ring. Alternatively, when R<sub>2</sub> is OH and X is N-H, they may be combined to form a heterocyclic ring structure, *e.g.* a morpholine ring.

In particular, the invention contemplates a family of amides with the generic structure shown below and active as cannabinoid receptor agonists having formula II:



wherein R is a saturated or unsaturated, substituted or unsubstituted hydrocarbyl group with from 15 to 29 carbon atoms, optionally incorporating up to 3 oxygen or sulfur atoms;

R<sub>3</sub> and R<sub>4</sub> are selected independently from hydrogen, alkyl (C1-4), alkenyl (C2-4), alkynyl (C2-4), cycloalkyl (C3-6), or hydroxyalkyl group with from 2 to 4 carbon atoms;


R<sub>2</sub> is OH or O-CO-alkyl, where the alkyl group has from 1 to 4 carbon atoms; and

n is selected from 2 to 4.



When R<sub>2</sub> is OH and X is N-H, they may be combined to form a heterocyclic ring structure.

The present invention also contemplates a family of esters with the generic structure shown below and active as cannabinoid receptor agonists having formula III:



5

wherein R is a saturated or unsaturated, substituted or unsubstituted hydrocarbyl group with from 15 to 29 carbon atoms, optionally incorporating up to 3 oxygen atoms;


10 R<sub>3</sub> and R<sub>4</sub> are selected independently from hydrogen, alkyl (C1-4), alkenyl (C2-4), alkynyl (C2-4), cycloalkyl (C3-6), or hydroxyalkyl group with from 2 to 4 carbon atoms;

R<sub>2</sub> is OH or O-CO-alkyl, where the alkyl group has from 1 to 4 carbon atoms; and

n is selected from 2 to 4.

15

The invention further contemplates a family of amides with the generic structure shown below and active as inhibitors of endogenous cannabinoid inactivation in accordance with the present invention having formula IV:



wherein R is a polyunsaturated, substituted or unsubstituted hydrocarbyl group with from 18 to 22 carbon atoms;

R<sub>2</sub> is selected independently from substituted or unsubstituted cycloalkyl (C3-  
 5 6) group and substituted or unsubstituted phenyl group (*e.g.*, p-hydroxyphenyl, p-hydroxy-o-methyl-phenyl).

The invention also contemplates a family of fatty acid derivatives with the generic structure shown below and active as inhibitors of endogenous cannabinoid inactivation having formula V:



10

wherein R<sub>1</sub> is a saturated or polyunsaturated, substituted or unsubstituted hydrocarbyl group with from 6 to 22 carbon atoms;

X is -C=O or SO<sub>2</sub>-; and

R<sub>2</sub> is a halogen or a halogen-substituted methyl group.

15 In accordance with another aspect of the present invention, there are disclosed pharmaceutical compositions for treating cough comprising the following examples of direct and indirect acting cannabinoid receptor agonists: arachidonylethanolamide

(anandamide), (R)-(+)-arachidonyl-1<sup>1</sup>-hydroxy-2<sup>1</sup>-propylamide, cis-7,10,13,16-docosatetraenoylethanolamide, homo-delta-linoleylethanolamide, N-propyl-arachidonylethanolamide, N-ethyl-arachidonylethanolamide, and 2-arachidonylglycerol. There are also disclosed pharmaceutical compositions for  
5 treating cough comprising the following examples of cannabinoid inactivation inhibitors: N-(4-hydroxyphenyl)-arachidonylamide, palmitylsulphonylfluoride, and arachidonyltrifluoromethylketone.

The cannabinoid receptor agonist and/or cannabinoid inactivation inhibitors, and pharmaceutically acceptable excipient, may, among other things, be formulated as  
10 an aerosol, spray, or solution, to be inhaled, to be administered orally, or to be administered parenterally, such as intravenously.

The locally acting cannabinoid receptor agonist and/or cannabinoid inactivation inhibitor, and pharmaceutically acceptable excipient, may be administered in conjunction with at least one additional therapeutic agent from the  
15 group consisting of anti-inflammatory compounds, systemic anti-tussives, and local anesthetics.

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and  
20 from the claims.

All publications, patents, patent applications, GenBank sequences and ATCC deposits cited herein are expressly incorporated by reference for all purposes.

## DESCRIPTION OF THE DRAWINGS

Figures 1A-C depict chemical structures of cannabinoid compounds and inhibitors of endogenous cannabinoid inactivation.

Figure 1A shows the general chemical structure of the direct-acting  
5 cannabinoid compounds of the present invention.

Figure 1B shows the general chemical structure of a representative cannabinoid inactivation inhibitor (inhibitor of anandamide transport).

Figure 1C shows the general chemical structure of another representative cannabinoid inactivation inhibitor (inhibitor of anandamide hydrolysis).

10 Figures 2A-C depict bar graphs summarizing data showing that anandamide inhibits capsaicin-evoked bronchospasm and cough in guinea pigs by activating peripheral CB1-type cannabinoid receptors. Results are expressed as mean  $\pm$  s.e.m, with  $n = 3$  for each condition. Asterisk indicates  $P < 0.01$ .

Figure 2A is a bar graph showing the constricting effect of capsaicin (Caps, 15 mg per kg, intravenous, i.v.) on guinea pig bronchial smooth muscle and its antagonism by the vanilloid receptor antagonist capsazepine (Cpz, 0.2 mg per kg, i.v.).

Figure 2B is a bar graph showing the dose-dependent inhibitory effects of anandamide (AEA, mg per kg, i.v.) on capsaicin (30 mg per kg)-evoked  
20 bronchospasm in the absence or presence of the CB1 antagonist SR141716A (SR1, 0.5 mg per kg, i.v.) or the CB2 antagonist SR144528 (SR2, 0.3 mg per kg, i.v.).

Figure 2C is a bar graph summarizing data showing the inhibitory effects of anandamide on capsaicin-evoked cough in the absence or presence of SR141716A (0.5 mg per kg, i.v.) or SR144528 (0.3 mg per kg, i.v.).

Figures 3A-E depict bar graphs and representative tracings of muscle tension showing that anandamide causes bronchoconstriction in vagotomized, atropine-treated guinea pigs by activating peripheral CB1 cannabinoid receptors. Asterisk indicates  $P < 0.01$ .

Figure 3A is a bar graph summarizing the dose-dependent effect of anandamide (AEA, mg per kg, i.v.) on bronchial smooth muscle, in the presence or absence of the CB1 antagonist SR141716A (SR1, 0.2 mg per kg, i.v.) ( $n = 6$  for each condition).

Figure 3B is a bar graph summarizing the dose-dependent effects of anandamide (5-30 mg per animal, intratracheal) in the absence or presence of SR141716A (SR1, 0.3 mg per kg, i.v.) ( $n = 6$  for each condition). SR141716A was administered 15 min before anandamide.

Figure 3C is a representative tracing illustrating the effect of anandamide (100  $\mu\text{M}$ ) on isotonic muscle tension in guinea pig parenchyma strips and its reversal by the CB1 antagonist SR141716A (1  $\mu\text{M}$ ).

Figure 3D is a response of the same lung strip of Figure 3C to histamine (His, 10  $\mu\text{M}$ ) shown for comparison. The upward deflections are caused by repeated washes of the lung strip.

Figure 3E is a bar graph summarizing the dose-dependent contractions of lung parenchyma in the presence of anandamide ( $\mu\text{M}$ ) and antagonism of this effect by SR141716A ( $1 \mu\text{M}$ ) ( $n = 6$  for each condition).

Figures 4A-G show localization of CB1 cannabinoid receptors on axon  
5 terminals and preterminal segments in rat lungs.

Figures 4A-B show silver-intensified gold particles labeling CB1 cannabinoid receptors, indicated by thin arrows, on serial sections of axon terminals in a bronchiole. Axon terminals containing small electron-translucent and large dense-core vesicles (thick arrow) are embedded in the collagen matrix and are surrounded  
10 by bronchial smooth muscle cells (BSM).

Figure 4C shows that, in some cases, cannabinoid receptor labeling was observed in proximity of vesicle clusters (arrowhead), indicating putative neurotransmitter release sites.

Figures 4D-E show serial sections in the adventitious layer reveal multiple  
15 axon terminals packed together into glial capsules.

Figures 4F-G show co-localization of cannabinoid receptor and neuropeptide Y (NPY) immunoreactivities. Immunogold labeling of CB1 receptors is visible on the membrane of axon terminals, labeled a1 and a2, filled with electron-dense NPY immunoreactivity. N indicates the nucleus of a putative Schwann cell. Scale bars:  
20  $0.2 \mu\text{m}$  (scales for Figure 4B and 4E are the same as in Figures 4A and 4D, respectively).

Figures 5A-B depict bar graphs showing the intrinsic effects of the CB1 antagonist SR141716A on capsaicin-evoked bronchospasm and cough. Results are expressed as mean $\pm$ s.e.m, with n = 6 for each condition. Asterisk indicates P < 0.05.

Figure 5A is a bar graph summarizing the bronchoconstricting effects of capsaicin (mg per animal, intratracheal) in the absence or presence of the CB1 antagonist SR141716A (0.2 mg per kg, i.v.).

Figure 5B is a bar graph summarizing the tussigenic effects of capsaicin (0.3  $\mu$ M, 4 min aerosol) in the absence or presence of SR141716A (0.2 mg per kg, i.v.).

Figures 6A-C depict the Ca<sup>2+</sup>-dependent biosynthesis of anandamide in rat lung tissue.

Figures 6A-B are representative high-performance liquid chromatography/mass spectrometry tracings for selected ions characteristic of endogenous anandamide (mass-to-charge ratio m/z = 370, an adduct with Na<sup>+</sup>, [M + Na<sup>+</sup>]) and synthetic [<sup>2</sup>H<sub>4</sub>]anandamide (m/z = 374, [M + Na<sup>+</sup>]), which was added to the samples as an internal standard, respectively.

Figure 6C is a bar graph summarizing the effects of EGTA (1 mM) or Ca<sup>2+</sup> (3 mM) on anandamide biosynthesis in rat lung membranes. Ca<sup>2+</sup> significantly stimulated anandamide formation (mean $\pm$ s.e.m., \* P < 0.05, n= 4).

Figures 7A-F depicts the structure and Ca<sup>2+</sup> dependent biosynthesis of anandamide precursors in rat lung tissue.

Figures 7A-B show the chemical structures of alk-1-palmitoenyl-2-arachidonyl-sn-glycero-phosphoethanolamine-N-arachidonyl (NAPE 1) and alk-1-stearyl-2-arachidonyl-sn-glycero-phosphoethanolamine-N-arachidonyl (NAPE 2), respectively, two putative anandamide precursors.

5        Figures 7C-D are representative high-performance liquid chromatography/mass spectrometry tracings for selected ions characteristic of NAPE 1 ( $m/z = 1009$ , deprotonated molecular ion,  $[M - H]^-$ ) and NAPE 2 ( $m/z = 1039$ ,  $[M - H]^-$ ), respectively.

10        Figures 7E-F are bar graphs summarizing that biosynthesis of NAPE 1 and NAPE 2, respectively, was significantly stimulated by incubation with  $Ca^{2+}$  (3 mM) (mean  $\pm$  s.e.m., \*  $P < 0.05$ ,  $n = 4$ ) as compared to EGTA. NAPE 2 was eluted from the column as a doublet and the areas under both peaks were combined for quantification.

Like reference symbols in the various drawings indicate like elements.

#### DETAILED DESCRIPTION

15        The invention provides methods for ameliorating cough by means of (1) local administration of anandamide and other cannabinoid compounds, such as those illustrated by formulae I, II, and III; and/or (2) local or systemic administration of agents that increase the levels of endogenous or exogenously added cannabinoids in the upper respiratory tract by inhibiting cannabinoid inactivation, such as those  
20        represented by formulae IV and V.



## Definitions

Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

The phrase “administration of a pharmaceutical composition” incorporates the phrases common usage and refers to any appropriate means to give a pharmaceutical to a patient, taking into consideration the properties of the pharmaceutical composition and the preferred site of administration; *e.g.*, in one embodiment, the pharmaceutical composition of the invention is inhaled into the lungs.

The term “ameliorating” as used herein refers to any indicia of success in the treatment or amelioration of an injury, pathology, condition, or symptom associated with a cough, including any objective or subjective parameter such as abatement; diminishing of symptoms or making the symptom, injury, pathology or condition more tolerable to the patient; decreasing the frequency or duration of the symptom or condition; improving a patient’s physical or mental well-being; and preventing the onset of the symptom or condition of coughing. The treatment or amelioration of symptoms can be based on any objective or subjective parameter; including, *e.g.*, the results of a patient’s observations, physical examination, or, simply an improvement in the patient’s sense of well-being.

The term “anandamide” as used herein refers to arachidonylethanolamides (see, *e.g.*, U.S. Patent No. 5,631,297) an endogenous lipid that activates cannabinoid

receptors and mimics the pharmacological effects of  $\Delta^9$ -tetrahydrocannabinol, the active principle of hashish and marijuana. Anandamide analogs (equivalents) are described, *e.g.*, in U.S. Patent No. 5,977,180; WO 99/60987; WO 99/64389. See also, *e.g.*, U.S. Patent Nos. 6,028,084; 6,013,648; 5,990,170; 5,925,672; 5,747,524;  
5 5,596,106; EP 0 570 920, WO 94-12466.

The term "locally acting cannabinoid" as used herein refers to cannabinoids of the general formulae I, II, or III. These cannabinoid analogs (equivalents) are described, *e.g.*, in U.S. Patent Nos. 5,635,530 and 5,618,955.

The term "direct cannabinoid receptor agonist" as used herein refers to a  
10 compound that binds to and activates CB1-type cannabinoid receptors.

The terms "indirect cannabinoid receptor agonist," "inhibitor of cannabinoid inactivation," or "cannabinoid inactivation inhibitor" as used herein refer to a compound that blocks the inactivating transport and/or degradation of cannabinoid compounds, consequently causing the accumulation of the cannabinoid substances at  
15 its sites of action.

The term "endogenous cannabinoid" as used herein refers to an endogenous agonist, or an equivalent thereof, of a cannabinoid receptor. Cannabinoid receptors are described, *e.g.*, in U.S. Patent No. 6,013,648. Endogenous agonists include, *e.g.*, 2-arachidonylglycerol or anandamide. See also U.S. Patent Nos. 6,028,084;  
20 6,017,919; 5,596,106; 5,990,170; and, Seltzman (1999) *Curr. Med. Chem.* 6:685-704.

The term "cough" as used herein refers to the act of coughing or to the psychological or physiological sensations associated with causing a cough that can be

ameliorated by administration of a pharmaceutical composition able to serve as a cannabinoid receptor agonist, to inhibit the inactivating transport (*e.g.*, the intracellular transport), and/or to inhibit anandamide hydrolysis of endogenous, or exogenously added, cannabinoid substances. The term "cough" is broadly defined  
5 and not limited to a particular disease or cause creating this condition.

While the invention is not limited by any particular mechanism of action, in one embodiment, the invention contemplates administration of the locally acting cannabinoid receptor agonists and/or administration of cannabinoid inactivation inhibitors, which inhibit the inactivating transport of cannabinoid substances, and/or  
10 inhibit the anandamide hydrolysis of cannabinoid substances, as described in further detail, below.

The phrase "inhibiting cannabinoid inactivation" means any measurable amount of increase in the amount of extracellular free cannabinoid substance. While the invention is not limited by any specific mechanism, the inhibition of inactivation  
15 can be accomplished by the pharmaceutical composition by inhibition of inactivating uptake of the cannabinoid substance by the cell membrane or inhibition of anandamide hydrolysis.

The term "pharmaceutically acceptable excipient" incorporates the common usage and includes any suitable pharmaceutical excipient, including, *e.g.*, water,  
20 saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose, lactose, or sucrose solutions, magnesium stearate, sodium stearate, glycerol monostearate, glycerol, propylene glycol, ethanol, and the like.

The terms "pharmaceutically effective" and "therapeutically effective" refer to a sufficient level of cough suppression or prevention in a human or animal resulting from the stimulation of cannabinoid or cannabinoid-like receptors. The term "therapeutically effective amount" and grammatical variations thereof refer to quantities of the active compound that are sufficient to produce the desired therapeutic effect when delivered topically (*e.g.*, by aerosol) or systemically (*e.g.*, orally).

### General Methods

The methods of the invention use compounds capable of ameliorating cough by providing locally acting cannabinoids, inhibiting the inactivating transport of cannabinoids, and/or inhibiting anandamide hydrolysis. A variety of exemplary compounds useful in these methods are described herein. Exemplary routine methods for identifying these compounds are described herein. Exemplary routine methods for identifying inhibiting the inactivating transport of cannabinoids can be found in Patent Application U.S.S.N 09/612,326, filed July 6, 2000, the entirety of which is incorporated herein by reference.

The skilled artisan will recognize that compounds useful in the methods of the invention (*e.g.*, arachidonylethanolamide) can be synthesized using a variety of procedures and methodologies, which are well described in the scientific and patent literature., *e.g.*, *Organic Syntheses Collective Volumes*, Gilman *et al.* (Eds) John Wiley & Sons, Inc., NY; Venuti (1989) *Pharm Res.* 6:867-873. The invention can be practiced in conjunction with any method or protocol known in the art, which are well

described in the scientific and patent literature. Therefore, only a few general techniques will be described prior to discussing specific methodologies and examples relative to the methods of the invention.

### **Structural Guidelines and Screening Tests to Design Locally Acting**

#### **5 Cannabinoids Useful in the Methods of the Invention**

In the methods of the invention, pharmaceutical compositions comprising compounds capable of ameliorating cough are administered. These compounds act by locally activating cannabinoid receptors. An exemplary locally acting compound is an anandamide.

10       The biological actions of anandamide (arachidonyl-ethanolamide), an endogenous cannabinoid lipid, in cough and bronchospasm inhibition is thought to be through the anandamide's activation of the CB1 receptors. Such actions are theorized by studies described herein using CB1 and CB2 receptor antagonists in the presence of locally acting cannabinoids. The experiments are described in greater detail below.

15       Furthermore, as described herein, the methods of the invention have been demonstrated to ameliorate cough by using art-accepted animal models. Specifically, the cannabinoids and their anti-tussive effects have been looked at in guinea pigs, rats, and cats, (Gordon, R. *et al.* (1976) *Eur. J. Pharmacol.* Vol. 35 (2):309-313). In summary, these exemplary techniques and guidelines provide clear parameters to  
20       select for compounds useful as pharmaceutical compositions in the methods of the invention.

Cannabinoids, such as anandamide, which can be found endogenously, produces a profound inhibition of cough and bronchial smooth muscle contraction, when administered either systemically or by local application in the airways. Figures 2A-C show bar graphs of the level of bronchospasm and cough in guinea-pigs after administration of capsaicin, the pungent principle of chili pepper. Similar data were obtained in rats (intratracheal administration: 10 mg per animal,  $41 \pm 6\%$  of maximal bronchospasm; 30 mg per animal,  $55 \pm 12\%$ ; 100 mg per animal,  $81 \pm 19\%$ ; mean  $\pm$  s.e.m.,  $n = 3$ ). This response was abrogated by anandamide when the compound was administered systemically before capsaicin in guinea pigs (Figure 2B). Similar results were obtained in rats (capsaicin, 10 mg per animal, intratracheal administration:  $37.2 \pm 4.2\%$  of maximal bronchospasm; capsaicin after anandamide, 1 mg per kg, i.v.,  $14 \pm 7\%$ ;  $n = 3$ ). This effect was completely reversed by the selective CB1 cannabinoid antagonist SR141716A, but only slightly reduced with a maximal dose of the CB2 antagonist SR144528. Palmitylethanolamide, a structural analog of anandamide that inhibits nociception in mice but does not interact with CB1 cannabinoid receptors as described in Calignano *et al.* (1998) *Nature* 394, 277-281, was ineffective at alleviating capsaicin-evoked bronchospasm. When given as an aerosol to conscious guinea pigs, capsaicin stimulates C-fibre activity in the upper respiratory tract and triggers cough. Systemic anandamide reduced capsaicin-evoked cough, an effect that was abrogated by CB1 cannabinoid receptor blockade, as shown in Figure 2C. Importantly, aerosolized anandamide also produced potent anti-tussive effects (Figure 2C), which were not accompanied by any visual signs of cannabinoid intoxication.

Anandamide had no direct bronchomotor action except at the highest dose tested (5 mg per kg), at which the compound elicited a small bronchoconstriction ( $11.8 \pm 5.9\%$  of maximal; mean  $\pm$  s.e.m.,  $n = 5$ ). To investigate further this response, the effects of anandamide in anesthetized rodents that were deprived of the bronchoconstricting tone conferred by the vagus nerve were examined. The effects are shown in Figures 3A-E. After vagotomy and administration of atropine (a cholinergic antagonist), which eliminate vagal influences, systemic application of anandamide produced a dose-dependent bronchoconstriction in guinea pigs and rats (i.v.; 1 mg per kg,  $0 \pm 0\%$  of maximal bronchospasm; 3 mg per kg,  $12 \pm 1.7\%$ ; 5 mg per kg,  $18.3 \pm 1.2\%$ ;  $n = 3$ ) in the presence and absence of SR141716A, as shown in Figure 3A. Similar effects were observed when anandamide was injected into the guinea pig bronchi via a tracheal catheter (Figure 3B), or applied to isolated strips of guinea pig lung parenchyma (Figure 3C-E). Figure 3C is a representative tracing illustrating the effect of anandamide on muscle tension in guinea pig parenchyma strips and its reversal by the CB1 antagonist SR141716A. Figure 3D is a representative tracing of the same lung strip of Figure 3C responding to histamine. Figure 3E shows the contractions of lung parenchyma by anandamide and antagonism by SR141716A. The slow onset of the anandamide response in guinea pig lung strips is consistent with results obtained in other isolated tissues, for example, as described in Devane, W. *et al.*, (1992) *Science* 258, 1946-1949, while the low potency of anandamide in this preparation may be accounted for by limited tissue penetration and/or rapid inactivation.

In agreement with this possibility, the anandamide transport inhibitor N-(4-hydroxyphenyl)-arachidonamide enhanced anandamide-evoked contractions in guinea

pig isolated lung strips (anandamide, 50  $\mu$ M,  $0.336 \pm 0.07$  dyne/mg of tissue; anandamide plus N-(4-hydroxyphenyl)-arachidonamide, 28  $\mu$ M,  $0.638 \pm 0.06$  dyne/mg of tissue;  $P < 0.05$ ,  $n = 6$ ). The CB1 antagonist SR141716A blocked anandamide bronchoconstriction *in vivo* and *in vitro* (Figures 3A-E), whereas the CB2 antagonist SR144528 had no such effect. The cannabinoid agonist HU210 was also potent at eliciting guinea pig bronchial muscle constriction after tracheal administration (0.1 mg per animal,  $10.0 \pm 0.6\%$  of maximal bronchospasm; 1 mg per animal,  $30 \pm 1.2\%$ ; 10 mg per animal,  $60 \pm 2.2\%$ ; 30 mg per animal, 100%;  $n=6$ ).

Anandamide has been claimed to activate vanilloid receptors. However, the vanilloid antagonist capsazepine had no effect on anandamide-evoked bronchospasm at a dose that completely prevented the capsaicin response (0.2 mg per kg, i.v.). These results indicate that removing the vagal excitatory tone unmasked a bronchoconstricting activity of anandamide mediated through CB1 cannabinoid receptors.

The ability of anandamide to influence bronchial muscle contractility after local administration suggests that this compound may exert its effects by activating CB1 cannabinoid receptors located within the airways. To test this possibility, the ultrastructural localization of CB1 cannabinoid receptors in rat lungs by electron microscopy, were examined using an antibody directed against the intracellular C-terminus of the rat CB1 cannabinoid receptor protein. Immunogold staining revealed that cannabinoid receptors are present on nerve fibers distributed amongst bronchial and bronchiolar smooth muscle cells, as shown in Figures 4A-C, or between the longitudinal and circular smooth muscle layers, where several axons were packed



together into glial capsules (Figures 4D-E). All bundles contained at least one CB1 cannabinoid receptor-positive axon.

Detailed evaluation (20 bundles consisting of 91 axons followed through at least 25 consecutive sections) revealed that 36% of the axons were labeled with the cannabinoid receptor antibody. The gold particles labeling cannabinoid receptors were attached to the inner surface of the axon plasma membrane, either at the release site or in the preterminal segments. This is consistent with the fact that our antibody recognizes the intracellular C-terminus of the CB1 cannabinoid receptor protein.

Axon terminals bearing cannabinoid receptor immunoreactivity were in close proximity to smooth muscle cells (0.2-0.5 mm) and contained a large number of small agranular vesicles along with few dense-core vesicles (Figures 4A-B). In some cases, cannabinoid receptor immunoreactivity was adjacent to clusters of vesicles accumulated at the plasma membrane, which most likely represent neurotransmitter release sites (Figure 4C).

In determining whether CB1 cannabinoid receptors are localized on noradrenergic and/or non-noradrenergic fibers, a combination of immunogold staining for CB1 cannabinoid receptors and immunoperoxidase staining for neuropeptide Y (NPY), a cotransmitter in sympathetic neurons, were used. We found that 63% of NPY-bearing axons were also CB1 receptor-positive (Figures 4F-G). Importantly, however, extensive labeling was observed on many NPY-negative axons, suggesting that both noradrenergic and/or non-noradrenergic nerves may express cannabinoid receptors.

The finding that cannabinoid receptors are found predominantly, if not exclusively, on axon terminals of airway nerves, suggests that anandamide regulates cough and bronchial smooth muscle tone through a prejunctional mechanism. Indeed, inhibition of excitatory neurotransmission in the airways may provide a parsimonious explanation for the ability of anandamide to oppose capsaicin-evoked cough and bronchospasm. This interpretation is further supported by the ability of anandamide and other cannabinoid agonists to inhibit neurotransmitter release in peripheral tissues and in the central nervous system. The mechanism underlying the constricting actions of anandamide in animals lacking cholinergic control is currently unknown. One possibility, which is consistent with the co-localization of CB1 cannabinoid receptors with NPY, is that anandamide inhibits the release of bronchodilating mediator(s). Alternatively, anandamide may interact with cannabinoid receptors on smooth muscle. The failure to detect CB1 cannabinoid receptor immunoreactivity in lung smooth muscle may have been caused by insufficient sensitivity of the technique used or by the presence in smooth muscle of a receptor variant that is not recognized by the antibody used. Interestingly, Northern blot analyses suggest that alveolar type II cells in the lung may express two different CB1 cannabinoid receptor mRNA species.

To test for the possibility that endogenous cannabinoids regulate airway responsiveness, the intrinsic effects of CB1 and CB2 antagonists on bronchospasm and cough in guinea pigs were determined. Blockade of CB1 cannabinoid receptors with SR141716A had no bronchomotor consequences per se, but significantly enhanced the bronchoconstriction and coughing evoked by capsaicin administered either via a tracheal catheter (Figures 5A-B) or by i.v. injection (30 mg per kg; capsaicin alone,  $55.3 \pm 8.2\%$  of maximal bronchospasm; capsaicin after SR141716A

[0.5 mg per kg, i.v.],  $92.3 \pm 3.4\%$ ;  $P < 0.05$ ,  $n = 3$ ). The CB2 antagonist SR144528 had no such effects. Although the bronchomotor actions of the CB1 antagonist may be accounted for by its inverse agonist properties, two lines of evidence suggest that this drug acted by opposing an ongoing cannabinoid modulation. First, the lack of effect seen with the CB1 antagonist in the absence of capsaicin is incompatible with an inverse agonist behavior. Second, analyses by high-performance liquid chromatography (HPLC) coupled to positive-ionization electrospray mass spectrometry (MS) revealed that anandamide is synthesized in rat lung tissue through a  $\text{Ca}^{2+}$  ion-activated mechanism (Figures 6A-B). Rat lung membranes produced on average  $0.6 \pm 0.2$  pmol of anandamide per mg of protein in the presence of the  $\text{Ca}^{2+}$  chelator, EGTA (1 mM); and  $1.6 \pm 0.2$  pmol of anandamide per mg of protein in the presence of  $\text{Ca}^{2+}$  (3 mM) (mean  $\pm$  s.e.m.,  $n = 4$ ;  $P < 0.05$  between EGTA and  $\text{Ca}^{2+}$ ; Student's  $t$  test) (Figure 6C). Guinea pig lung membranes produced  $0.9 \pm 0.3$  pmol of anandamide per mg of protein in the presence of EGTA; and  $8.8 \pm 1.2$  pmol of anandamide per mg of protein in the presence of  $\text{Ca}^{2+}$  ( $n = 4$ ;  $P < 0.0001$ ; Student's  $t$  test).

Anandamide is thought to originate from the enzymatic cleavage of N-arachidonyl phosphatidylethanolamine (NAPE), the biosynthesis of which is catalyzed by a  $\text{Ca}^{2+}$ -dependent N-acyltransferase activity as described in Di Marzo, V. *et al.* (1994) *Nature*, 372, 686-691; Sugiura, T. *et al.* (1996) *Eur. J. Biochem.*, 240, 53-62; Cadas, H. *et al.* (1997) *J. Neurosci.*, 17, 1226-1242. Using negative ionization electrospray HPLC/MS, two molecular species of NAPE in lipid extracts of rat lung membranes: alk-1-palmitoonyl-2-arachidonyl-sn-glycero-phosphoethanolamine-N-arachidonyl (NAPE 1), depicted in Figure 7A, and alk-1-stearyl-2-arachidonyl-sn-

glycero-phosphoethanolamine-N-arachidonyl (NAPE 2), depicted in Figure 7B were identified. Identifications were based (1) on the occurrence of deprotonated molecules of appropriate mass (NAPE 1: mass-to-charge ratio ( $m/z$ ) 1009; and NAPE 2,  $m/z$  1039); and (2) on the chromatographic behavior of these components, which was similar to that of synthetic NAPE (Figures 7C-D). NAPE 1 and NAPE 2 were synthesized by rat lung membranes in a  $Ca^{2+}$ -dependent manner. The membranes produced  $1.5 \pm 0.02$  pmol of NAPE 1 and undetectable levels in NAPE 2 when incubated with EGTA (1 mM); and  $4.4 \pm 0.5$  pmol of NAPE 1 and  $3.1 \pm 0.6$  pmol of NAPE 2 when incubated with  $Ca^{2+}$  (3 mM) ( $n = 4$ ;  $P < 0.05$  between EGTA and  $Ca^{2+}$ ) (Figures 7E-F). Guinea pig lung membranes also produced NAPE 1 and NAPE 2 in a  $Ca^{2+}$ -dependent manner. The presence in rodent lungs of a  $Ca^{2+}$ -activated mechanism for the biosynthesis of anandamide and its phospholipid precursor supports a role for this endogenous cannabinoid in airway modulation. This suggests in turn that inhibitors of anandamide inactivation (compounds of formulae IV and IV) may also produce cough inhibition and bronchodilation by means of their ability to cause accumulation of anandamide at its sites of action.


These results demonstrate that activation of CB1 cannabinoid receptors by locally released cannabinoid compounds, such as anandamide, participates in the control of cough and bronchial contractility. How cannabinoids exert their control on bronchial contractility may depend, however, on the state of the bronchial muscle. When the muscle is contracted, as during capsaicin-evoked bronchospasm, anandamide may counteract this contraction, possibly by inhibiting the prejunctional release of excitatory neurotransmitters and neuropeptides. In contrast, when the

smooth muscle is relaxed, as seen after removal of the constricting influence of the vagus nerve, anandamides may cause bronchoconstriction.

In summary, the present results suggest that local applications of cannabinoid agents in the airways of animals whose vagal tone is not compromised, result in cough inhibition. These effects are mediated by activation of CB1 cannabinoid receptors located on peripheral terminals of airway nerves. Furthermore, the results suggest that local or systemic administration of inhibitors of endogenous cannabinoid inactivation may also result in cough inhibition. Since the animal models used in the present experiments are predictive of anti-tussive actions/treatments in humans, it is anticipated that comparable cough-suppressing effects will be produced in human patients affected by pathological tussigenic conditions. These conditions include, but are not limited to, persistent dry cough, cancer-induced cough, and angiotensin-converting enzyme (ACE) inhibitor-induced cough.

The present invention discloses a method for treating cough in a mammal through application of at least one direct or indirect cannabinoid receptor agonist that is active at relieving or preventing cough by a peripheral action in the upper airways. The method comprises the step of administering to the mammal a cough-alleviating or cough-preventing amount of a pharmaceutical formulation comprising at least one compound having the general formulae I, II, III, IV, or V described below.

Formula I:



wherein X is N-R1 or O;

R is a saturated or unsaturated, chiral or achiral, cyclic or acyclic, substituted  
 5 or unsubstituted hydrocarbyl group with 11 to 29 carbon atoms, optionally  
 incorporating up to 6 oxygen or sulfur atoms;


R1, R3 and R4 are selected independently from hydrogen, alkyl (C1-4),  
 alkenyl (C2-4), alkynyl (C2-4), cycloalkyl (C3-6), or hydroxyalkyl group with from 2  
 to 4 carbon atoms;

10 R2 is OH or O-CO-alkyl, where the alkyl group has from 1 to 4 carbon atoms;  
 and

n is selected from 2 to 4.

When R2 is OH and X is N-H, they may be combined through the carbonyl  
 group to form a heterocyclic ring structure, *e.g.* an oxazolidinone ring. Alternatively,  
 15 when R2 is OH and X is N-H, they may be combined to form a heterocyclic ring  
 structure, *e.g.* a morpholine ring.

Formula II:



wherein R is a saturated or unsaturated, substituted or unsubstituted hydrocarbyl group with from 15 to 29 carbon atoms, optionally incorporating up to 3  
 5 oxygen or sulfur atoms;

R3 and R4 are selected independently from hydrogen, alkyl (C1-4), alkenyl (C2-4), alkynyl (C2-4), cycloalkyl (C3-6), or hydroxyalkyl group with from 2 to 4 carbon atoms;


R2 is OH or O-CO-alkyl, where the alkyl group has from 1 to 4 carbon atoms;

10 and

n is selected from 2 to 4.

When R2 is OH and X is N-H, they may be combined to form a heterocyclic ring structure.

Formula III:




wherein R is a saturated or unsaturated, substituted or unsubstituted hydrocarbyl group with from 15 to 29 carbon atoms, optionally incorporating up to 3  
 5 oxygen atoms;

R<sub>3</sub> and R<sub>4</sub> are selected independently from hydrogen, alkyl (C1-4), alkenyl (C2-4), alkynyl (C2-4), cycloalkyl (C3-6), or hydroxyalkyl group with from 2 to 4 carbon atoms;

R<sub>2</sub> is OH or O-CO-alkyl, where the alkyl group has from 1 to 4 carbon atoms;  
 10 and

n is selected from 2 to 4.

Formula IV:





wherein R is a polyunsaturated, substituted or unsubstituted hydrocarbyl group with from 18 to 22 carbon atoms;

R2 is selected independently from substituted or unsubstituted cycloalkyl (C3-6) group and substituted or unsubstituted phenyl group (*e.g.*, *p*-hydroxyphenyl, *p*-hydroxy-*o*-methyl-phenyl).

Formula V:



wherein R1 is a saturated or polyunsaturated, substituted or unsubstituted hydrocarbyl group with from 6 to 22 carbon atoms;

10 X is -C=O or SO<sub>2</sub>-; and

R2 is a halogen or a halogen-substituted methyl group.

#### Pharmaceutical formulations

The pharmaceutical compositions used in the methods of the invention can be administered by any means known in the art, *e.g.*, parenterally, topically, orally, or by local administration, such as aerosol or transdermally. The pharmaceutical compositions can be formulated in any way and can be administered in a variety of unit dosage forms depending upon the condition, disease, degree, or cause of the cough, the general medical condition of the patient, the resulting preferred method of administration and the like. Routine means to determine drug regimens, formulations,

and administration to practice the methods of the invention are well described in the patent and scientific literature, see, *e.g.*, the latest edition of *Remington's Pharmaceutical Sciences*, Maack Publishing Co, Easton PA.

Pharmaceutical formulations can be prepared according to any method known  
5 to the art for the manufacture of pharmaceuticals. The pharmacological composition of the invention can comprise other active agents such as anti-inflammatory compounds. Pharmaceutically acceptable compounds can contain a physiologically acceptable compound that acts to stabilize the composition or to increase or decrease the absorption of the agent and/or pharmaceutical composition. A formulation can be  
10 admixed with nontoxic pharmaceutically acceptable excipients that are suitable for manufacture.

Pharmaceutical formulations for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in appropriate and suitable dosages. Such carriers enable the pharmaceuticals to be formulated in unit dosage  
15 forms as tablets, pills, powder, dragees, capsules, liquids, lozenges, gels, syrups, slurries, suspensions, *etc.*, suitable for ingestion by the patient. Pharmaceutical preparations for oral use can be obtained through combination of cannabinoids of the invention with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable additional compounds, if  
20 desired, to obtain tablets or dragee cores. Suitable solid excipients such as carbohydrate or protein fillers include, *e.g.*, sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxy-

methylcellulose; and gums including arabic and tragacanth; and proteins, *e.g.*, gelatin and collagen. Disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

5           Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of  
10   active compound (*i.e.*, dosage). Pharmaceutical preparations of the invention can also be used orally using, *e.g.*, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules can contain active agents mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft  
15   capsules, the active agents can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Aqueous suspensions can contain an active agent (*e.g.*, N-(4-hydroxyphenyl) arachidonamide) in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium  
20   carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (*e.g.*, lecithin), a condensation product of an alkylene oxide with a fatty acid (*e.g.*, polyoxyethylene

stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono-oleate). The aqueous suspension can also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin. Formulations can be adjusted for osmolarity.

Oil-based pharmaceuticals are particularly useful for administration of hydrophobic active agents. Oil-based suspensions can be formulated by suspending an active agent (e.g., N-(4-hydroxyphenyl) arachidonamide) in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin; or a mixture of these. See e.g., U.S. Patent No. 5,716,928 describing using essential oils or essential oil components for increasing bioavailability and reducing inter- and intra-individual variability of orally administered hydrophobic pharmaceutical compounds (see also U.S. Patent No. 5,858,401). The oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents can be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose. These formulations can be preserved by the addition of an antioxidant such as ascorbic acid. As an example of an injectable oil vehicle, see Minto (1997) *J. Pharmacol. Exp. Ther.* 281:93-102.

The pharmaceutical formulations of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring  
5 phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsion can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs. Such formulations can also contain a  
10 demulcent, a preservative, or a coloring agent.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water can be formulated in admixture with a dispersing, suspending and/or wetting agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above.  
15 Additional excipients, *e.g.*, sweetening, flavoring and coloring agents, can also be present.

In the methods of the invention, the pharmaceutical compounds can also be administered by intranasal or intrabronchial routes including insufflation, powders, and aerosol formulations (for examples of steroid inhalants, see Rohatagi (1995) *J. Clin. Pharmacol.* 35:1187-1193; Tjwa (1995) *Ann. Allergy Asthma Immunol.* 75:107-  
20 111). For example, aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also may be formulated as pharmaceuticals for non-pressured preparations such as in

a nebulizer or an atomizer. Typically, such administration is in an aqueous pharmacologically acceptable buffer.

In the methods of the invention, the pharmaceutical compounds can be delivered transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.

In the methods of the invention, the pharmaceutical compounds can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of the drug, which is slowly released subcutaneously; see Rao (1995) *J. Biomater Sci. Polym.* Ed. 7:623-645; as biodegradable and injectable gel formulations, see, *e.g.*, Gao (1995) *Pharm. Res.* 12:857-863 (1995); or, as microspheres for oral administration, see, *e.g.*, Eyles (1997) *J. Pharm. Pharmacol.* 49:669-674. Both transdermal and intradermal routes afford constant delivery for weeks or months.

In the methods of the invention, the pharmaceutical compounds can be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, *etc.* Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder in 1 mM to 50 mM histidine, 0.1% to 2% sucrose, 2% to 7% mannitol at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

In the methods of the invention, the pharmaceutical compounds can be parenterally administered, such as by intravenous (IV) administration. These formulations will commonly comprise a solution of active agent dissolved in a pharmaceutically acceptable carrier. Acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride. In addition, sterile fixed oils can conventionally be employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can likewise be used in the preparation of injectables. These solutions are sterile and generally free of undesirable matter. These formulations may be sterilized by conventional, well-known sterilization techniques. The formulations may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, *e.g.*, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient's needs. For IV administration, the formulation can be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated using those suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1,3-butanediol.

In another embodiment, the formulations of the invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, *e.g.*,

by employing ligands attached to the liposome, or attached directly to the oligonucleotide, that bind to surface membrane protein receptors of the cell resulting in endocytosis. By using liposomes, particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the active agent into target cells *in vivo*. See, *e.g.*, U.S. Patent Nos. 6,063,400; 6,007,839; Al-Muhammed (1996) *J. Microencapsul.* 13:293-306; Chonn (1995) *Curr. Opin. Biotechnol.* 6:698-708; Ostro (1989) *Am. J. Hosp. Pharm.* 46:1576-1587.

In the methods of the invention, a pharmaceutical composition is administered in an amount sufficient to ameliorate cough. The amount of pharmaceutical composition adequate to accomplish this is defined as a "therapeutically effective dose." The dosage schedule and amounts effective for this use, *i.e.*, the "dosing regimen," will depend upon a variety of factors, including the stage and/or severity of the disease, condition, or other cause of the cough, the severity of the cough, the general state of the patient's health, the patient's physical status, age and the like. In calculating the dosage regimen for a patient, the mode of administration also is taken into consideration.

The dosage regimen also takes into consideration pharmacokinetics parameters well known in the art, *i.e.*, the active agents' rate of absorption, bioavailability, metabolism, clearance, and the like (see, *e.g.*, Hidalgo-Aragones (1996) *J. Steroid Biochem. Mol. Biol.* 58:611-617; Groning (1996) *Pharmazie* 51:337-341; Fotherby (1996) *Contraception* 54:59-69; Johnson (1995) *J. Pharm. Sci.* 84:1144-1146; Rohatagi (1995) *Pharmazie* 50:610-613; Brophy (1983) *Eur. J. Clin.*



*Pharmacol.* 24:103-108; the latest Remington's, *supra*). The state of the art allows the clinician to determine the dosage regimen for each individual patient, active agent and disease or condition treated. Guidelines provided for similar compositions used as pharmaceuticals can be used as guidance to determine the dosage regiment, *e.g.*,  
5 dose schedule and dosage levels of any CB1 cannabinoid receptor activator administered practicing the methods of the invention.

Single or multiple administrations of formulations can be given depending on the dosage and frequency as required and tolerated by the patient. The formulations should provide a sufficient quantity of active agent to effectively treat the cough. In  
10 one example, the concentration of cannabinoid compounds, such as anandamide, in the pharmaceutically acceptable excipient is between about 0.1-100 mg per dose in an aqueous solution. As another example, one typical pharmaceutical formulations for oral administration of N-(4-hydroxyphenyl) arachidonamide is in a daily amount of between about 0.5 to about 20 mg per kilogram of body weight per day. In an  
15 alternative embodiment, dosages are from about 1 mg to about 4 mg per kg of body weight per patient per day are used. Lower dosages can be used, particularly when the drug is administered to an anatomically secluded site, such as the lung space, in contrast to administration systemically into the blood stream. Substantially higher dosages can be used in topical administration. Actual methods for preparing  
20 parenterally administrable formulations will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's, *supra*. See also Nieman, In "Receptor Mediated Antisteroid Action," Agarwal, *et al.* (1987) eds., De Gruyter, New York.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following examples are to be considered illustrative and thus are not limiting of the remainder of the disclosure in any way whatsoever.

## 5    **EXAMPLE 1**

### **Chemical synthesis**

Anandamide and other fatty acid ethanolamides can be synthesized following standard procedures described in Giuffrida, A. *et al.* (1998) *FEBS Lett.*, 422, 373-376. The synthesis of 2-arachidonyleglycerol and other monoacylglycerides can be  
10    accomplished as described in B. Serdarevich, (1967) *Journal of the Oil Chemist Society*, 44, 381-393. The drugs were dissolved in dimethylsulphoxide (DMSO), and administered in physiological saline containing 10% DMSO.

## **EXAMPLE 2**

### **Biological assays**

15        **Bronchospasm.** Dunkin-Hartley guinea pigs (Charles-River, weighing 200-400 g) or Wistar rats (Charles-River, weighing 200-300 g) were anesthetized with pentobarbital (40 mg per k.g., intraperitoneal) and fentanyl (25 mg per kg, intramuscular). The trachea and carotid artery were catheterized to measure airway obstruction and systemic blood pressure. The jugular vein was catheterized to  
20    administer drugs. Pancuronium bromide (4 mg per kg, intravenous) was administered to prevent spontaneous breathing. The animals were ventilated with room air using a

rodent ventilator (U. Basile, Comerio, Italy) run at 60 strokes per min; stroke volume was 3-7 ml. Airway resistance was measured by using a differential pressure transducer (U. Basile) connected by the side-arm of the tracheal catheter to a bronchospasm transducer. Bronchospasm was expressed as a percent of the maximal response, which was determined by clamping the tracheal catheter before and after each experiment. Drugs were dissolved in saline containing 10% dimethylsulphoxide, and injected via the jugular vein. Responses were evaluated at their peak. Arterial blood pressure was measured continuously with a pressure transducer connected to a recorder (U. Basile). To abolish vagal influences on bronchial musculature, in some experiments the vagus nerves were bilaterally transected and administered with atropine sulfate (2 mg per kg, i.v.).

**Cough.** Conscious guinea pigs were individually exposed for 4 min to aerosolized capsaicin (0.3 mM) while recording coughs by using a microphone placed in the exposure chamber as described in Bolser, D.C., *et al.* (1995) (*Eur. J. Pharmacol.*, 276, R1-R3). Each animal was treated only once with capsaicin. Aerosols were prepared with an Air Lister Basic apparatus (Hatù, Italy), regulated at an emission flow rate of 6 liters per min.

**Isolated lung strips.** Guinea pig parenchimal strips were prepared essentially as described in Samhoun, M.N., *et al.* (1984) *Prostaglandins*, 27, 711-724. The strips were placed in 10-ml organ baths containing Krebs' buffer (in mM: NaCl, 118; KCl, 4; K<sub>2</sub>HPO<sub>4</sub>, 1.2; MgSO<sub>4</sub>, 1.2; CaCl<sub>2</sub>, 2.5; NaHCO<sub>3</sub>, 25.0; glucose, 11.2; supplemented with 7 mM atropine sulfate and 15 mM indomethacin) at 37°C and aerated with an oxygen/carbon dioxide mixture (95/5%). Muscle contractions were

recorded with an isometric force transducer (U. Basile) and expressed in dyne per mg of fresh tissue.

### EXAMPLE 3

#### Electron microscopy

5       The lungs were removed from 3 rats perfused with a phosphate-buffered (PB, 0.1 M) fixative containing 4% paraformaldehyde, 0.2% picric acid and 0.05% glutaraldehyde, and were further fixed for 24 h. Immunohistochemical analyses were conducted as described in Katona, I. *et al.* (1999) *J. Neurosci.*, 19, 4544-4558. Rabbit C-terminal anti-CB1 and anti-NPY antibodies were used at 1:5000 and 1:20,000  
10       dilution, respectively. The specificity of the NPY antibody was reported previously in Csiffary, A., *et al.* (1990) *Brain Res.* 506, 215-222.

### EXAMPLE 4

#### Membrane preparation and lipid extraction

      Lung particulate fractions were prepared as described in Désarnaud, F., *et al.*  
15       (1995) *J. Biol. Chem.*, 270, 6030-6035. Incubations were performed for 1 h at 37°C in Tris buffer (50 mM, pH 7.4) containing CaCl<sub>2</sub> (3 mM) or EGTA (1 mM) and 2 mg per ml of membrane protein. Reactions were stopped by adding cold methanol and the lipids were extracted with chloroform. Before HPLC/MS analysis, anandamide and NAPE were fractionated by silica gel column chromatography as described in  
20       Cadas, H., *et al.* (1997) *J. Neurosci.*, 17, 1226-1242.

**EXAMPLE 5****High performance liquid chromatography/mass spectrometry****(HPLC/MS)**

The anandamide was identified and quantified by reversed-phase HPLC coupled to positive ionization electrospray MS, by using an isotope-dilution method described in Giuffrida, A., Rodríguez de Fonseca, F., *et al.* (2000) *Anal. Biochem.*, 280, 87-93. NAPE species were purified by reversed-phase HPLC on a C18 Bondapak column (300x3.9 mm I.D., 5 mm) (Waters) maintained at 20°C and interfaced with an Agilent HP1100 model mass spectrometer. HPLC conditions consisted of a linear gradient of methanol in water (from 75% to 100% methanol in 30 min) with a flow rate of 1 ml/min. Under these conditions, different NAPE species were eluted from the column as a group of peaks at retention times comprised between 27 and 29 min. MS analyses were performed with the electrospray ion source set in the negative ionization mode, the Vcap set at 5 kV, and the fragmentor voltage set at 200 V. Nitrogen was used as a drying gas at a flow rate of 12 l/min. The drying gas temperature was set at 350°C and the nebulizer pressure at 30 PSI. For quantitative purposes, diagnostic ions (deprotonated molecular ions, (M - H)<sup>-</sup>) were extracted from full scan data and quantified by comparison with an external standard (1-palmityl-2-oleyl-sn-glycero-phosphoethanolamine-N-arachidonyl, Avanti Polar Lipids).

**EXAMPLE 6****Data analysis**

Results are expressed as means $\pm$ s.e.m. The significance of differences among groups was evaluated using Student's *t* test or analysis of variance followed by


5 Dunnett's test.

All publications, Genebank references, patents, patent applications cited herein are hereby expressly incorporated by reference for all purposes. A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit  
10 and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

## WHAT IS CLAIMED IS:

1. A method of ameliorating cough comprising the local administration to the upper respiratory airways of a subject in need of such treatment of a cannabinoid

5 compound of formula I:



wherein X is N-R1 or O;

10 R is a saturated or unsaturated, chiral or achiral, cyclic or acyclic, substituted or unsubstituted hydrocarbyl group with 11 to 29 carbon atoms;

R1, R3 and R4 are selected independently from hydrogen, alkyl (C1-4), alkenyl (C2-4), alkynyl (C2-4), cycloalkyl (C3-6), or hydroxyalkyl group with from 2 to 4 carbon atoms;

15 R2 is OH or O-CO-alkyl, where the alkyl group has from 1 to 4 carbon atoms; and


n is selected from 2 to 4.

2. The method of claim 1 wherein R comprises 1 to 6 oxygen or sulfur atoms.

3. The method of claim 1 wherein R<sub>2</sub> is OH and X is N-H, and wherein they combine through the carbonyl group to form a heterocyclic ring structure.

4. The method of claim 3 wherein the heterocyclic ring structure is selected from the group consisting of an oxazolidinone ring and a morpholine ring.

5. A method of ameliorating cough comprising the local administration to the upper respiratory airways of a subject in need of such treatment of a cannabinoid compound of formula II:



wherein R is a saturated or unsaturated, substituted or unsubstituted hydrocarbyl group with from 15 to 29 carbon atoms;

R<sub>3</sub> and R<sub>4</sub> are selected independently from hydrogen, alkyl (C1-4), alkenyl (C2-4), alkynyl (C2-4), cycloalkyl (C3-6), or hydroxyalkyl group with from 2 to 4 carbon atoms;

R<sub>2</sub> is OH or O-CO-alkyl, where the alkyl group has from 1 to 4 carbon atoms; and

n is selected from 2 to 4.


6. The method of claim 5 wherein R comprises 1 to 3 oxygen or sulfur atoms.



7. The method of claim 5 wherein R<sub>2</sub> is OH and X is N-H, and wherein they combine to form a heterocyclic ring structure.

8. A method of ameliorating cough comprising the local administration to the upper respiratory airways of a subject in need of such treatment of a cannabinoid

5 compound of formula III:



wherein R is a saturated or unsaturated, substituted or unsubstituted hydrocarbyl group with from 15 to 29 carbon atoms;

10 R<sub>3</sub> and R<sub>4</sub> are selected independently from hydrogen, alkyl (C1-4), alkenyl (C2-4), alkynyl (C2-4), cycloalkyl (C3-6), or hydroxyalkyl group with from 2 to 4 carbon atoms;


R<sub>2</sub> is OH or O-CO-alkyl, where the alkyl group has from 1 to 4 carbon atoms; and

n is selected from 2 to 4.

15 9. The method of claim 8 wherein R comprises 1 to 3 oxygen atoms.

10. A method of ameliorating cough comprising the local administration to the upper respiratory airways of a subject or the systemic administration to subject in

need of such treatment of an inhibitor of endogenous cannabinoid inactivation of  
formula IV:



wherein R is a polyunsaturated, substituted or unsubstituted hydrocarbyl group  
5 with from 18 to 22 carbon atoms;

R<sub>2</sub> is selected independently from substituted or unsubstituted cycloalkyl (C<sub>3</sub>-  
6) group and substituted or unsubstituted phenyl group.

11. The method of claim 10 wherein the phenyl group is selected from the  
group consisting of p-hydroxyphenyl and p-hydroxy-o-methyl-phenyl.

10 12. A method of ameliorating cough comprising the local administration to  
the upper respiratory airways of a subject or the systemic administration to subject in  
need of such treatment of an inhibitor of endogenous cannabinoid inactivation of  
formula V:



15 wherein R<sub>1</sub> is a saturated or polyunsaturated, substituted or unsubstituted  
hydrocarbyl group with from 6 to 22 carbon atoms;

X is -C=O or SO<sub>2</sub>-; and

R2 is a halogen or a halogen-substituted methyl group.

13. The method of claim 1 wherein the cause of the cough can be persisting dry cough resulting from airway irritation and/or infection, angiotensin converting enzyme (ACE) inhibitors-induced cough, and cancer-induced cough.

5        14. The method of claim 10 wherein the method further comprises administration of a cannabinoid compound of formulae I, II, III, or any combination thereof.

10       15. The method of claim 11 wherein the method further comprises administration of a cannabinoid compound of formulae I, II, III, or any combination thereof.

16. A method of ameliorating cough comprising the local administration of a cannabinoid compound of formulae I, II, III, or any combination thereof, to the upper respiratory airways of patients in need of such treatment and whose vagal control of airway responsiveness is functional.

15       17. A method of selectively activating CB1 cannabinoid receptors of the upper respiratory airways, comprising locally administering to a subject in need of such treatment a cannabinoid compound of formulae I, II, III, or any combination thereof.

20       18. A method of ameliorating cough comprising the local administration to the upper respiratory airways of patients in need of such treatment, wherein the

cannabinoid compound is sensitive to metabolic inactivation by transport or hydrolysis, causing clinically insignificant systemic side effects.

19. The method of claim 1 wherein a cannabinoid of formulae I is selected from the group consisting of arachidonylethanolamide (anandamide), (R)-  
5 (+)arachidonyl-1<sup>1</sup>-hydroxy-2<sup>1</sup>-propylamide, cis-7,10,13,16-docosatetraenoylethanolamide, homo-delta-linoleyethanolamide, and N-propyl-arachidonylethanolamide.

20. The method of claim 10 wherein a cannabinoid inactivation inhibitor of formula IV is 4-(hydroxylphenyl)-arachidonylamide.

10 21. The method of claim 12 wherein a cannabinoid inactivation inhibitor of formula V is palmitylsulphonylfluoride or arachidonyltrifluoromethylketone.

22. A method of ameliorating cough comprising the local administration to the upper respiratory airways of a subject in need of such treatment of a pharmaceutical composition comprising a cannabinoid compound of formulae I, II,  
15 III, or any combination thereof.

23. The method of claim 22 wherein the method further comprises local or systemic administration of a pharmaceutical composition comprising a cannabinoid inactivation inhibitor of formulae IV, V, or any combination thereof.

24. The method of claim 23 wherein the pharmaceutical composition  
20 comprises compounds of formulae I, II, III, IV, V, or any combination thereof.

25. The method of claim 22, wherein the pharmaceutical composition is formulated for local delivery.

26. The method of claim 25 wherein the formulation for local delivery is by aerosol.

5        27. The method of claim 23 wherein the pharmaceutical composition is formulated for local delivery.

28. The method of claim 27 wherein the formulation for local delivery is by aerosol.

10       29. The method of claim 23 wherein the pharmaceutical composition is formulated for systemic delivery.

30. The method of claim 29 wherein the formulation for systemic delivery is by oral administration or intravenous administration.

15       31. A pharmaceutical composition comprising a locally acting cannabinoid of formulae I, II, III, or any combination thereof, wherein the cannabinoid ameliorates cough and produces, at most, clinically insignificant side effects.


32. The pharmaceutical composition of claim 31 further comprising a pharmaceutically acceptable excipient.

33. A pharmaceutical composition comprising a cannabinoid inactivation inhibitor of formulae IV, V, or any combination thereof, wherein the cannabinoid


inactivation inhibitor ameliorates cough and produces, at most, clinically insignificant side effects.

34. The pharmaceutical composition of claim 33 further comprising a pharmaceutically acceptable excipient.

Formula I:



Formula II:



Formula III:




Figure 1A

Formula IV:




Figure 1B

Formula V:



Figure 1C






Figure 2A

Figure 2B

Figure 2C




Figure 3A




Figure 3B




Figure 3C




Figure 3D




Figure 3E



Figure 4A



Figure 4B



Figure 4C



Figure 4D




Figure 4E




Figure 4F



Figure 4G




Figure 5A




Figure 5B






Figure 6C






Figure 7A




Figure 7B




Figure 7C




Figure 7D




Figure 7E




Figure 7F

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/16880

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61L 9/04; A61K 31/135, 31/13

US CL : 424/45; 514/654, 665, 666

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/45; 514/654, 665, 666

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,464,378 A (HUSSAIN) 07 August 1984 (07.08.1984) see entire document.	1-34
Y	Database Medline on STN, Accession No. 1998082798, SHAMSUDDIN et al. 'Regulation of leukotriene and platelet-activating factor synthesis in human alveolar macrophages'. J. Lab. And Clin. Med. December 1997, Vol. 130, No. 6, pages 615-626, see abstract.	1-34
Y	STENGEL et al. Pulmonary actions of anandamide, an endogenous cannabinoid receptor agonist, in guinea pigs. European Journal of Pharmacology. January 1998, Vol. 355, pages 57-66 see entire document.	1-34
Y	ZHU et al. Cytosolic Phospholipase A2 Activation is Essential for beta 1 and beta 2 Integrin-Dependent Adhesion of Human Eosinophils. Journal of Immunology. July 1999, Volume 163, No. 6, pages 3423-3429, see entire document.	1-34
Y,P	DE PETROCELLIS et al. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chemistry and Physics of Lipids. June 2000, Vol. 108, No. 1-2 pages 191-209, see entire document.	1-34
A, P	SUGIURA et al. 2-Arachidonoylglycerol and the cannabinoid receptors. Chemistry and Physics of Lipids. June 2000, Vol. 108, No. 1-2 pages 89-106, see entire document.	1-34



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 July 2001 (25.07.2001)

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Date of mailing of the international search report

04 SEP 2001

Authorized officer

Donna A. Jagoe

Telephone No. (703) 308-0193



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/16880

## Continuation of B. FIELDS SEARCHED Item 3:

WEST 2.0, STN, file cluster MEDICINE: search terms: cough or bronchospasm or asthma, cannab?, anandamide, arachidonylethanolamide, inhaler or aerosol or atomizer or mist or spray, cannabinoid inactivation inhibit?

